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3 Centre Atenció Primària (CAP) Canaletes, Institut Català de la Salut (ICS), Passeig d’Horta 17, 08290 Cerdanyola del Vallès, Spain
Correspondence should be addressed to Jordi Félez, jordifelez@gmail.com
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The NB4 promyelocytic cell line exhibits many of the characteristics of acute promyelocytic leukemia blast cells, including the
translocation (15 : 17) that fuses the PML gene on chromosome 15 to the RARα gene on chromosome 17. These cells have a very
high fibrinolytic capacity. In addition to a high secretion of urokinase, NB4 cells exhibit a 10-fold higher plasminogen binding
capacity compared with other leukemic cell lines. When tissue-type plasminogen activator was added to acid-treated cells, plasmin
generation was 20–26-fold higher than that generated by U937 cells or peripheral blood neutrophils, respectively. We found that
plasminogen bound to these cells can be detected by fluorescence-activated cell sorting using an antiplasminogen monoclonal
antibody that specifically reacts with this antigen when it is bound to cell surfaces. All-trans retinoid acid treatment of NB4 cells
markedly decreased the binding of this monoclonal antibody. This cell line constitutes a unique model to explore plasminogen
binding and activation on cell surfaces that can be modulated by all-trans retinoid acid treatment.
1. Introduction
Interaction of components of the plasminogen system
with fibrin or extracellular matrix promotes plasminogen
activation [1]. In a similar way, when components of the
plasminogen system are bound to cell surfaces, plasmin
generation is increased [2–4]. Binding of plasminogen to cell
surfaces is the most important event in the enhancement
of plasmin-mediated pericellular proteolysis. Plasminogen
binding has two major consequences: (1) plasminogen
activation by either tissue-type plasminogen activator (tPA)
or urokinase (uPA) is enhanced when plasminogen is bound
to cells [5, 6] and (2) plasmin generated on the cell surface
is protected from α2-antiplasmin [4, 7], arming the cell with
a more efficient proteolytic activity [5]. The promotion of
plasminogen activation by cells can be explained by kinetic
interactions with and on the cell surface, conformational
effects, and/or receptor occupancy [5].
The amount of plasminogen bound to cell surfaces can be
quantified. By using radiolabeled plasminogen, it is possible
to detect specific binding of plasminogen to cells and to
calculate binding affinities and the number of plasminogen
binding sites. With this approach, a wide number of cell
types have been analyzed (reviewed in [8]). In humans,
platelets and all nucleated cells bind plasminogen with a
Kd in the 0.3 to 2.8 μM range in agreement with the
plasminogen concentration in plasma (1-2 μM). Cells exhibit
a high capacity for plasminogen ranging from 104–105
binding sites for most nontransformed cells to 105–107 for
malignant cells and human umbilical vein endothelial cells.
In general, plasminogen binding capacity is paralleled by the
capacity of the cells to promote plasminogen activation. For
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example, in studies of plasminogen receptor modulation, it
has been demonstrated that upmodulation of plasminogen
binding sites, a process that can be induced by several
effectors, induces an increase in the promotion of plasmin
generation by cells [9]. Among malignant cells, the study
of fibrinolysis on acute promyelocytic leukemia (APL) cells
offered new insights in the understanding of this disease and
its hemorrhagic complications.
APL is due to a clonal proliferation of promyelocytic blast
cells carrying the t(15 : 17) that fuses the PML gene on chro-
mosome 15 to the RARα gene on chromosome 17 [10, 11]. In
contrast to other leukemic processes, APL onset is frequently
associated with life-threatening bleeding complications due
to disseminated intravascular coagulation, abnormal fibri-
nolysis, or both [10–12]. Immature promyelocytes secrete
high amounts of uPA [13, 14] that can promote plasmin
formation in vivo and cause abnormal bleeding. In addition,
a mechanism of promotion of plasminogen activation by
cell surfaces has been explored on APL blast cells and on
the promyelocytic cell line NB4. This promyelocytic cell line
carries the typical translocation found in APL blast cells and
has been used in a wide variety of biological studies on APL.
The introduction of all-trans retinoid acid (ATRA) in the
treatment of this disease in the nineties has dramatically
changed the outcome of APL. In most APL patients, ATRA
treatment induces differentiation of immature promyelocytic
cells and corrects bleeding disorders. ATRA has several
dramatic effects on the hemostatic system on both APL blast
cells and on NB4 cells [15].
In this study, we sought to characterize plasminogen
binding to NB4 cells using three different approaches. First,
using radiolabeled plasminogen, we analyzed the plasmino-
gen binding capacity of NB4 cells compared with other
leukemic cells lines of different lineages. Second, we explored
the functional consequences of plasminogen activation on
NB4 cell surfaces analyzing plasmin generation by these
cells. Finally, we measured plasminogen bound to this cell
line by fluorescence-activated cell sorting analysis using
an antiplasminogen monoclonal antibody that specifically
interacts with plasminogen bound to cell surfaces [16] and
explored the effect of ATRA treatment of NB4 cells on
plasminogen binding.
2. Material and Methods
2.1. Proteins, Protein Iodination, and Antibodies. Glu-
plasminogen was obtained from Chromogenix (Mölndal,
Sweden). tPA (Actilyse) and high-molecular-weight uPA
were obtained from Boehringer Ingelheim and Roger Labo-
ratories (Molins de Rei-Barcelona, Spain), respectively. Glu-
plasminogen was radiolabeled using a modified chloramine
T method [17]. The labeled and unlabeled preparations of
plasminogen used in this study had the characteristics of
previously described preparations from our laboratory [17–
20]. Antiplasminogen monoclonal antibody 49 (mAb49)
was raised and characterized as previously described [16].
Fluorescein isothiocyanate (FITC) conjugated goat anti-
mouse monoclonal antibodies were from Sera-Lab, Ltd.
2.2. Cells. Neutrophils, monocytes, and lymphocytes were
isolated from blood collected into heparin (5 U/mL) as
described [21]. NB4 cells were provided by Dr. M. Lanotte
(Hôpital St. Louis, Paris, France). The human cell line,
Nalm6, was provided by Dr. J. Inglés-Esteve (IDIBELL,
Barcelona). Other cell lines were from the American Type
Tissue Culture Collection (ATCC) and cultured in RPMI-
1640 (Bio-Whitakker/MA Bioproducts) containing 1 mM Na
pyruvate and 5–10% fetal bovine serum. Blast cells from
peripheral blood were analyzed from a patient with acute
nonlymphoblastic leukemia (ANLL), categorized according
to the FAB classification [22].
2.3. Ligand Binding Analyses. Ligand binding analyses were
performed as previously described by separating bound from
free ligand by centrifugation over 20% sucrose [17–20].
Molecules of ligand bound per cell were calculated based on
the specific activities of the radiolabeled ligands.
2.4. Cell-Dependent Promotion of Plasminogen Activation.
Plasminogen activation studies were carried out in microtitre
plates in reaction volumes of 100 μL as previously described
[5, 6]. Briefly, 20 μL of plasminogen activators (tPA or uPA)
(final concentration 70 and 37 pmol/L, resp.) were mixed
with 40 μL of cells (final concentration 1.5 × 106 cells/mL)
and 40 μL of substrate mix containing Glu-plasminogen
(final concentration 100 nmol/L) and chromogenic substrate
S-2251 (Val-Leu-Lys-p-nitroanilide; Chromogenix) (final
concentration 0.15 mmol/L). Reactions were performed in
assay buffer consisting of Tris-HCl, pH 7.4, at 37◦C, and
a final ionic strength of 0.12, containing 1 mg/mL human
serum albumin. Absorbance was monitored at 405 nm, using
a Thermomax thermostatted plate reader (Molecular Devices
Corporation, Stanford, CA). Rates of plasmin generation
were calculated as previously described [5, 6].
2.5. Fluorescence-Activated Cell Sorting (FACS) Analysis.
Cells were washed with PBS containing 1% BSA and 0.1%
sodium azide (PBA), incubated with PBA containing 10%
heat-inactivated normal rabbit serum, washed again, and
incubated with mAb49 (130 nM) or isotype control, washed,
and then stained with FITC-goat anti-mouse IgG, which
was detected in a flow cytometry analyzer (Coulter’s EPICS
XL-MCL). Plasminogen binding to cells in whole peripheral
blood collected into EDTA was determined as above with
the following exceptions. Cells were incubated in 10% heat-
inactivated human AB serum in PBS, washed with PBA and
incubated with anti-mouse IgG conjugated to PE, washed
and incubated with FITC-conjugated antibodies to specific
leukocyte antigens. Cells were incubated in Ortho-mune
Lysing Reagent (Ortho Diagnostic Systems Inc.), centrifuged,
and resuspended in PBA containing 7-aminoactynomycion
D (Molecular Probes) at 1 mg/mL.
2.6. Reagents. Heparin, Tween 80, Tween 20, ε-ACA, and
bovine serum albumin were from Sigma (St. Louis, MO). All-
trans retinoic acid was from Hoffmanm-La Roche.
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Table 1: Plasminogen binding to cell surfaces of several leukemic
cell lines and normal peripheral blood cells.
Cell type Cell lineage
Molecules of plasminogen
bound/cell (×106)
NB4 Promyelocytic 38.0± 1.8
KG1a Myeloblastoid 1.5± 0.2
K562 Erythromyeloid 3.1± 0.2
HL-60 Promyeloid 1.7± 0.3
U937 Monocytoid 2.0± 0.7
THP-1 Monocytoid 1.6± 0.2
Nalm6 Pre-B-Cell 1.2± 0.2




Binding analyses were carried out by incubation of washed cells (2–5 ×
106/mL) with radiolabeled plasminogen (100 nM) in a total volume of
200 μL for 2 hours a 4◦C. Cells were then separate from the whole reaction
mixture by centrifugation of aliquots in 20% sucrose solution. The specific
binding of radiolabeled plasminogen was determined by subtracting counts
bound in the presence of 0.15 M ε-ACA. Results are the mean ± SD of 2–4
separate experiments.
Neutrophils, monocytes, lymphocytes, and RBC were
isolated from blood collected into heparin (5 U/mL), theo-
phylline (10 mM), and prostaglandin E1α (10 U/mL) (Sigma)
as described [6].
3. Results
3.1. Plasminogen Binding Capacity of NB4 Promyelocytic Cells.
To explore the plasminogen binding capacity of this cell line
with respect to other leukemic cells lines and peripheral
blood cells, radiolabeled plasminogen (100 nmol/L) was
added to washed cells (2–5 × 106/mL) and incubated for
1 hr at 37◦C. After incubation, free ligand was separated
by centrifugation on 20% sucrose. Specific binding was
calculated by subtracting counts bound in the presence
of 0.15 mol/L ε-ACA. Under these conditions, NB4 cells
specifically bound 38.0±0.7×106 molecules of plasminogen
per cell. For comparison, plasminogen binding was also
explored on several leukemic cell lines of distinct lineages and
in several types of normal peripheral blood cells. As shown in
Table 1, NB4 cells bound plasminogen with a capacity at least
one order of magnitude higher than the other cells analyzed.
3.2. Functional Consequences of Plasminogen Binding to NB4
Cells. Plasminogen binding to leukocytoid cells promotes
plasmin formation in the presence of either tPA or uPA
plasminogen activators [4–6, 22–26]. In previous kinetic
studies, we have demonstrated that plasmin generation is
promoted by leukocytoid cells by 60- to 30-fold when tPA
or uPA, respectively, was used as plasminogen activators [5–
9]. With a similar approach, we explored the promotion of
plasminogen activation by NB4 cells.
NB4 cells secrete high amounts of uPA [10, 13]. uPA has a
high affinity for uPA receptors, and an autocrine mechanism
of saturation of uPA receptors has been previously described
in several cell lines [27]. To assess whether NB4 cells could
promote plasmin formation in the absence of extrinsic
plasminogen activators, washed cells were incubated with
plasminogen and the rate of plasminogen activation was
measured as previously described [5, 6]. Under this condi-
tions, NB4 cells generated 0.3 ± 0.01 pmol/L of plasmin ·
sec−1, whereas 0.07 ± 0.02 and 0.06 ± 0.01 pmol/L of
plasmin · sec−1 were generated by U937 cells or peripheral
blood neutrophils, respectively. These data suggested that a
significant fraction of uPA secreted by NB4 cells was bound
to their cell surface and could activate plasminogen.
To better define the role of plasminogen binding sites in
the promotion of plasmin formation, NB4 cells were acid
treated to remove uPA from uPA receptors. Following acid
treatment, <0.01 pmol/L · sec−1 of plasmin was generated
when cells were incubated with plasminogen, indicating that
the uPA was efficiently removed from cells by this treatment.
Acid-treated NB4 cells were incubated with plasminogen
and tPA and the rate of plasminogen activation determined.
Under these conditions, plasmin generation on acid treated
NB4 cells was 0.8 ± 0.04 pmol/L · sec−1 while U937 and
peripheral blood neutrophils generated 0.3±0.08 and 0.016±
0.04 pmol/L · sec−1. of plasmin, respectively. Taken together,
these data suggested that the high number of plasminogen
binding sites detected on NB4 cells was paralleled by a high
capacity to promote plasminogen activation on their cell
surface.
3.3. Detection of Plasminogen Bound to the Cell Surface of NB4
Cells. To explore whether plasminogen could be detected on
the cell surface of NB4 cells, we used an antiplasminogen
monoclonal antibody (mAb49) that recognizes receptor-
induced binding sites (RIBSs) in plasminogen and, therefore,
preferentially react with cell-associated plasminogen in the
presence of soluble plasminogen [16]. Cells were washed
and incubated with plasminogen (10 μmol/L) for 1 hr at
37◦C. Then, mAb49 was added to the system and processed
for FACS analyses as described in Section 2. As depicted in
Figure 1, mAb49 detected plasminogen bound to these cells.
The mean fluorescence intensity was 2.2-fold higher in the
system containing added plasminogen (5.5 units) than in the
negative control without plasminogen (2.5 units).
To assess whether plasminogen binding changes induced
by ATRA treatment of NB4 cells [12, 29] could also be
detected by mAb49, these cells were treated for 48 hour
with 5 μM ATRA. The positive FACS signal observed with
untreated NB4 cells, preincubated with plasminogen, was
markedly decreased after treatment of NB4 cells with ATRA
for 48 hr (Figure 2(a)). For comparison, we explored with a
similar approach blast cells from a patient with APL with
a large proportion of blast cells (80%), both prior to and
after ATRA treatment in vivo. A strong FACS signal with
mAb49 was detected prior to ATRA treatment compared
with the isotype control (Figure 2(b)). After both a 4-day
and a 5-day of treatment with ATRA, blast cells exhibited a













Figure 1: Detection of plasminogen bound to the surface of
NB4 cells. Cells (5 × 105) were washed with PBS containing 1%
BSA and 0.1% sodium azide (PBA) and incubated with 10 μM
plasminogen (black tracing) or buffer (blue tracing) for 1 hour
at 37◦C, washed again and incubated with PBA containing 10%
heat-inactivated normal rabbit serum for 10 minutes a room
temperature. As an additional control, NB4 cells were treated
with carboxypeptidase B (200 U/mL) before adding plasminogen
(teal tracing). After incubation, supernatants were removed by
centrifugation, incubated with mAb49 (130 nM) for 30 minutes
a 4◦C, washed and then stained with FITC-goat anti-mouse IgG,
which was detected by FACS analyses. This research was originally
published in [28].
markedly decreased FACS signal, compared with untreated
cells (Figure 2(b)). As an additional control, FACS analysis
of M1 blast cells (that have not been reported to bind
plasminogen) with mAb49 did not show a positive signal
compared with isotype control (Figure 2(c)).
Taken together, these results demonstrate that mAb49
can be used to monitor modulation of plasminogen to NB4
cells following ATRA treatment. Changes induced by ATRA
are similar to the ones observed in blast cells of patients with
APL.
4. Discussion
In this study, we have characterized plasminogen binding
to the NB4 promyelocytic leukemia cell line by analyzing
plasminogen binding to these cells in comparison to other
blood cell lines or peripheral blood cells. The functional
consequences of the high capacity of plasminogen binding by
NB4 cells were explored in kinetic studies measuring plasmin
generation. In addition, plasminogen binding to NB4 cells
was also explored using an antiplasminogen monoclonal
antibody that specifically recognizes plasminogen bound to
cells. This antibody allows detection of downmodulation of
plasminogen binding induced by ATRA treatment of these
cells.
NB4 cells exhibited a high capacity for binding of plas-
minogen. This capacity is one order of magnitude higher
than that displayed by other leukemic cells lines of distinct
lineages and two order of magnitude higher than normal
peripheral nucleated blood cells. Thus, the NB4 cell line
has the highest capacity for plasminogen among the cell
lines tested. This characteristic is also complemented with
a high capacity to produce uPA and therefore NB4 cells
have been used as models to study the bleeding comp-
lications of APL patients [10–15, 29–31]. The high plas-
minogen binding capacity of NB4 cells has been related
to the overexpression of plasminogen binding molecules.
Several proteins have been identified as cell surface binding
molecules for plasminogen, including α-enolase, annexin
II, tissue factor, and the complex S100A10-Annexin II [7–
9, 12, 29–39]. Although annexin II was highly expressed by
NB4 and APL blast cells antiannexin II antibodies reduce
plasminogen activation mediated by these cells by 35%,
ε-aminocaproic acid (EACA) gave a 71% reduction [12].
Because EACA inhibits the interaction of plasminogen with
cells, this result implies that other plasminogen receptors in
addition to annexin II could be important for stimulation of
plasminogen activation. An antibody to S100A10 molecule
fully blocks endothelial cell plasmin production [40], but
no data have been generated using this antibody on NB4
or APL cells. A monoclonal antibody to α-enolase (11G1)
blocks the cell surface promotion of plasminogen activation
in a wide variety of leukemic cell lines and abrogates NB4
mediated plasminogen activation by 70–80% [41]. Thus,
in addition to the Annexin II-S100A10 complex, α-enolase
also mediates plasminogen binding to NB4 cells. Tissue
factor is also a plasminogen-binding molecule [39] but
very high concentrations of soluble TF are required to
reduce plasminogen binding or cell-dependent promotion of
plasminogen activation. Thus, the physiological role of TF in
APL blast cells as a plasminogen binding molecule should be
further studied.
NB4 cells secrete high amounts of uPA, and therefore
we explore the capacity of these cells to promote plasmin
generation in the absence of added plasminogen activators.
Under these conditions, NB4 cells generated plasmin with
a 4-5-fold higher efficiency that U937 cells or peripheral
blood neutrophils. When tPA was added to acid-treated cells,
promotion of plasmin generation by NB4 cells was 20–26-
fold greater than by U937 cells or neutrophils, respectively.
These data suggest a parallelism between plasminogen
binding capacity and promotion of plasmin formation on
NB4 cell surfaces.
In flow cytometric and radioimmunometric studies,
we have previously demonstrated that a fraction of blood
plasminogen is bound to surfaces of peripheral nucleated
blood cells and platelets. In these studies, plasminogen
bound to cells was detected using a monoclonal antibody
to plasminogen which preferentially reacts with plasminogen
bound to cell surfaces, suggesting that plasminogen binding
to cells induces a conformational change in plasminogen and
that latent epitopes in soluble plasminogen become available
when plasminogen is bound to cells. These antibodies
detect receptor-induced binding sites (RIBS) in plasminogen
induced by its interaction with cells. Thus, they have been
named RIBS antibodies (see details in [16]). A practical












































Figure 2: In vitro and in vivo ATRA modulation of plasminogen binding to NB4 cells and APL blast cells. (a) NB4 cells were incubated
with 1 μM all-trans retinoic acid (ATRA) for 48 hours, washed and preincubated with plasminogen (10 μM) followed by FACS analyses with
mAb49 (orange tracing). FACS analyses with mAb49 of untreated NB4 cells preincubated with either plasminogen (black tracing) or buffer
(blue tracing) detected by antiplasminogen mAb49. (b) Plasminogen bound to blast cells from a patient with APL (CD33+; HLDR Negative)
was monitorized in whole blood using mAb49. Analyses were performed at day 0 of ATRA treatment (red tracing) and after ATRA treatment
for either 4 days (orange tracing) or 5 days (pink tracing). As a negative control FACS analysis with an isotype control antibody (turquoise
tracing). (c) FACS analysis using mAb49 (red tracing) or isotype control (turquoise tracing) of blood from a patient with an M1 leukemia.
This research was originally published in [28].
application of the use of antiplasminogen RIBS antibody
has been explored on acute promyelocytic leukemia (APL)
blast cells. This antibody gives a clear positive signal in
FACS analyses and can be used to explore changes in the
amount of plasminogen bound to blast cells in whole blood
during all-trans retinoid acid (ATRA) treatment of APL
patients [41]. Similar results were also obtained here with
NB4 cells. Plasminogen was detected on NB4 cells incubated
with plasminogen, whereas culture of NB4 cells with ATRA
for 48 hours markedly reduced the antiplasminogen RIBS
signal [41]. Again, these data reinforce the similarity between
APL blast cells and the NB4 cell line. In recent studies, ATRA
treatment of NB4 cells induces a downregulation of the
plasminogen-binding molecule S100A10 that is paralleled by
reduction in fibrinolytic activity [29]. In addition, depletion
of S100A10 by RNA interference abrogates cell-dependent
fibrinolytic activity in NB4 cells. Thus, these cells constitute
an excellent model to explore the modulation of plasminogen
binding to cells using mAb49.
5. Conclusions
Taken together, these data suggest that the NB4 cell line
constitutes a unique cell model for plasmin generation on
cell surfaces. The individual contribution of molecules that
bind plasminogen on these cells should be explored in future
6 Journal of Biomedicine and Biotechnology
studies. In addition, the downregulation of plasminogen
receptors induced by ATRA treatment of NB4 cells offers an
exciting model to study the modulation of these receptors
and their functional consequences.
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[10] R. P. Warrell, H. de Thé, Z. Y. Wang, and L. Degos,
“Acute promyelocytic leukemia,” The New England Journal of
Medicine, vol. 329, no. 3, pp. 177–189, 1993.
[11] L. Degos, “The history of acute promyelocytic leukaemia,”
British Journal of Haematology, vol. 122, no. 4, pp. 539–553,
2003.
[12] J. S. Menell, G. M. Cesarman, A. T. Jacovina, M. A. McLaugh-
lin, E. A. Lev, and K. A. Hajjar, “Annexin II and bleeding in
acute promyelocytic leukemia,” The New England Journal of
Medicine, vol. 340, no. 13, pp. 994–1004, 1999.
[13] L. Devy, P. Hollender, C. Munaut et al., “Matrix and ser-
ine protease expression during leukemic cell differentiation
induced by aclacinomycin and all-trans-retinoic acid,” Bio-
chemical Pharmacology, vol. 63, no. 2, pp. 179–189, 2002.
[14] H. Tapiovaara, S. Matikainen, M. Hurme, and A. Vaheri,
“Induction of differentiation of promyelocytic NB4 cells by
retinoic acid is associated with rapid increase in uroki-
nase activity subsequently downregulated by production of
inhibitors,” Blood, vol. 83, no. 7, pp. 1883–1891, 1994.
[15] T. Barbui, G. Finazzi, and A. Falanga, “The impact of all-trans-
retinoic acid on the coagulopathy of acute promyelocytic
leukemia,” Blood, vol. 91, no. 9, pp. 3093–3102, 1998.
[16] J. Han, N. Baik, K. H. Kim et al., “Monoclonal antibodies
detect receptor-induced binding sites in Glu-plasminogen,”
Blood, vol. 118, no. 6, pp. 1653–1662, 2011.
[17] L. A. Miles and E. F. Plow, “Binding and activation of
plasminogen on the platelet surface,” The Journal of Biological
Chemistry, vol. 260, no. 7, pp. 4303–4311, 1985.
[18] L. A. Miles, M. H. Ginsberg, J. G. White, and E. F. Plow,
“Plasminogen interacts with human platelets through two
distinct mechanisms,” Journal of Clinical Investigation, vol. 77,
no. 6, pp. 2001–2009, 1986.
[19] L. A. Miles, C. M. Dahlberg, and E. F. Plow, “The cell-binding
domains of plasminogen and their function in plasma,” The
Journal of Biological Chemistry, vol. 263, no. 24, pp. 11928–
11934, 1988.
[20] J. Felez, L. A. Miles, J. Plescia, and E. F. Plow, “Regulation of
plasminogen receptor expression on human monocytes and
monocytoid cell lines,” Journal of Cell Biology, vol. 111, no. 4,
pp. 1673–1683, 1990.
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